COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis

被引:5
|
作者
Yang, Xueying [1 ,2 ]
Zhang, Jiajia [2 ,3 ]
Liu, Ziang [2 ,3 ]
Chen, Shujie [2 ,3 ]
Olatosi, Bankole [2 ,4 ]
Poland, Gregory A. [5 ]
Weissman, Sharon [2 ,6 ]
Li, Xiaoming [1 ,2 ]
机构
[1] Univ South Carolina, Arnold Sch Publ Hlth, Dept Hlth Promot Educ & Behav, Columbia, SC 29208 USA
[2] Univ South Carolina, South Carolina SmartState Ctr Healthcare Qual, Columbia, SC 29208 USA
[3] Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC USA
[4] Univ South Carolina, Arnold Sch Publ Hlth, Dept Hlth Serv Policy & Management, Columbia, SC USA
[5] Mayo Clin & Foundat, Mayo Vaccine Res Grp, Rochester, MN USA
[6] Univ South Carolina, Sch Med, Dept Internal Med, Columbia, SC USA
基金
美国国家卫生研究院;
关键词
COVID-19; HIV/AIDS; Breakthrough infections; Propensity score matching; VACCINE; IMMUNOGENICITY; RISK;
D O I
10.1016/j.ijid.2023.11.029
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: This study aims to characterize and compare COVID-19 breakthrough infections between people living with and without HIV across different phases of the pandemic.Methods: Using statewide HIV cohort data, the study population included adult residents in South Carolina (SC) ( > 18 years old) who were fully vaccinated between January 02, 2021 and April 14, 2022 when Alpha, Delta, and Omicron variants were circulating in SC. We used the Cox proportional hazard model to investigate the association between HIV infection and breakthrough infection, adjusting for relevant covariates.Results: Among 2,144,415 vaccinated individuals, 8,335 were people living with HIV (PLWH) and 2,136,080 were people without HIV (PWoH). After propensity score matching, HIV infection was not significantly as-sociated with breakthrough infection rate. However, when comparing breakthrough infections among in-dividuals without any booster dose, PLWH had a higher risk of breakthrough infections (adjusted Hazard Ration: 1.19; 95% confidence interval: 1.03-1.39). Compared to PWoH, PLWH with high levels of clusters of differentiation 4 (CD4) count or viral suppression were not associated with breakthrough infections.Conclusions: Our findings do not support a broad conclusion that COVID-19 vaccine effectiveness is lower among PLWH, while we did find that PLWH had a higher risk of breakthrough infection compared to PWoH if they did not receive a booster dose.(c) 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
引用
收藏
页码:21 / 27
页数:7
相关论文
共 50 条
  • [21] COVID-19 infection in people living with HIV
    Brolly, Jacob
    Chadwick, David R.
    BRITISH MEDICAL BULLETIN, 2023, 147 (01) : 20 - 30
  • [22] Safety profiles of homologous and heterologous regimens containing three major types of COVID-19 vaccine among people living with HIV
    Khawcharoenporn, Thana
    Hanvivattanakul, Sirashat
    INTERNATIONAL JOURNAL OF STD & AIDS, 2024, 35 (04) : 262 - 273
  • [23] Breakthrough COVID-19 Infections after Booster SARS-CoV-2 Vaccination in a Greek Cohort of People Living with HIV during the Delta and Omicron Waves
    Protopapas, Konstantinos
    Thomas, Konstantinos
    Moschopoulos, Charalampos D.
    Oktapoda, Eirini
    Marousi, Eirini
    Marselou, Eirini
    Stamoulis, Nikiforos
    Filis, Christos
    Kazakou, Pinelopi
    Oikonomopoulou, Chrysanthi
    Zampetas, Georgios
    Efstratiadou, Ourania
    Chavatza, Katerina
    Kavatha, Dimitra
    Antoniadou, Anastasia
    Papadopoulos, Antonios
    BIOMEDICINES, 2024, 12 (07)
  • [24] Willingness to accept COVID-19 vaccination among people living with HIV in a high HIV prevalence community
    Govere-Hwenje, Sabina
    Jarolimova, Jana
    Yan, Joyce
    Khumalo, Anele
    Zondi, Gugulami
    Ngcobo, Marcia
    Wara, Nafisa J.
    Zionts, Dani
    Bogart, Laura M.
    Parker, Robert A.
    Bassett, Ingrid, V
    BMC PUBLIC HEALTH, 2022, 22 (01)
  • [25] Preventative behaviours and COVID-19 infection in a Canadian cohort of people living with HIV
    Hammond, Keely
    Lee, Terry
    Vulesevic, Branka
    Singer, Joel
    Needham, Judy
    Burchell, Ann N.
    Samji, Hasina
    Walmsley, Sharon
    Hull, Mark
    Jenabian, Mohammad-Ali
    Routy, Jean-Pierre
    Margolese, Shari
    Mandarino, Enrico
    Anis, Aslam H.
    Cooper, Curtis L.
    Costiniuk, Cecilia T.
    AIDS RESEARCH AND THERAPY, 2023, 20 (01)
  • [26] Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis
    Kang, Liangyu
    Shang, Weijing
    Gao, Peng
    Wang, Yaping
    Liu, Jue
    Liu, Min
    VACCINES, 2022, 10 (09)
  • [27] COVID-19 vaccination willingness among people living with HIV in Shijiazhuang, China: a cross-sectional survey
    Zhang, Xihong
    Zhan, Haoting
    Wang, Lijing
    Liu, Yongmei
    Guo, Xinru
    Li, Chen
    Li, Xiaomeng
    Li, Beilei
    Li, Haolong
    Li, Yingxia
    Chen, Qian
    Gao, Huixia
    Feng, Fumin
    Li, Yongzhe
    Dai, Erhei
    FRONTIERS IN MEDICINE, 2024, 11
  • [28] COVID-19 Breakthrough Infections in Vaccinated Kidney Transplant Recipients
    Zhang, Xiaojing
    Weng, Ruopeng
    Liu, Fei
    Xie, Yi
    Jin, Yanyan
    Li, Qiuyu
    Huang, Guoping
    Chen, Junyi
    Wang, Jingjing
    Shen, Huijun
    Fu, Haidong
    Mao, Jianhua
    VACCINES, 2022, 10 (11)
  • [29] Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic
    Alcendor, Donald J.
    Matthews-Juarez, Patricia
    Smoot, Duane
    Hildreth, James E. K.
    Lamar, Kimberly
    Tabatabai, Mohammad
    Wilus, Derek
    Juarez, Paul D.
    VACCINES, 2022, 10 (05)
  • [30] Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA
    Mazzitelli, Maria
    Trunfio, Mattia
    Sasset, Lolita
    Leoni, Davide
    Castelli, Eleonora
    Lo Menzo, Sara
    Gardin, Samuele
    Putaggio, Cristina
    Brundu, Monica
    Garzotto, Pietro
    Cattelan, Anna Maria
    VIRUSES-BASEL, 2022, 14 (03):